XML 19 R10.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Segment Data
 3 Months Ended
Jun. 30, 2011
Segment Data  
Segment Data

6.              Segment Data

 

The Company adopted SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information now codified as ASC 280. ASC 280 designates the internal reporting that is used by management for making operating decisions and assessing performance as the source of the Company’s reportable segments. ASC 280 also requires disclosure about products and sources, geographic areas and major customers. The Company aggregates its product lines as two reportable segments based on the similar characteristics and markets of our product lines.

 

Revenues related to operations in the U.S. and foreign countries for the three month periods ended June 30, 2011 and 2010 are presented below. Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported. Net revenues from unaffiliated customers and long-lived assets related to continuing operations in the U.S. and foreign countries as of June 30, 2011 and 2010 are as follows:

 

 

 

Quarter Ended June 30

 

(Dollars in thousands)

 

2011

 

2010

 

Net revenues from unaffiliated customers:

 

 

 

 

 

United States

 

$

5,493

 

$

4,908

 

Foreign (no country exceeds 10% of total)

 

3,395

 

2,547

 

 

 

$

8,888

 

$

7,455

 

 

 

 

June 30, 2011

 

June. 30, 2010

 

Long-lived assets at end of quarter:

 

 

 

 

 

United States

 

$

33,368

 

$

28,572

 

 

The following table summarizes total sales by product for the three month periods ended June 30:

 

 

 

Three Months Ended June 30

 

(Dollars in thousands)

 

2011

 

2010

 

 

 

 

 

 

 

Instrumentation Products

 

$

4,339

 

$

4,000

 

Biological Indicators

 

4,549

 

3,455

 

Total Sales

 

$

8,888

 

$

7,455

 

 

Following is the Company’s additional business segment information for June 30, 2011 and 2010:

 

(Dollars in thousands)

 

Biological
Indicators

 

Instrumentation
Products

 

Total

 

Quarter Ended June 30, 2011

 

 

 

 

 

 

 

Revenue

 

$

4,549

 

$

4,339

 

$

8,888

 

Operating Income

 

$

941

 

$

1,752

 

$

2,693

 

Other (Income) and Expense

 

$

53

 

$

(3

)

$

50

 

Total Assets

 

$

32,164

 

$

20,038

 

$

52,202

 

Capital Expenditures

 

$

99

 

$

62

 

$

161

 

Depreciation

 

$

113

 

$

52

 

$

165

 

Amortization

 

$

336

 

$

40

 

$

376

 

 

 

 

 

 

 

 

 

Quarter Ended June 30, 2010

 

 

 

 

 

 

 

Revenue

 

$

3,455

 

$

4,000

 

$

7,455

 

Operating Income

 

$

718

 

$

1,496

 

$

2,214

 

Other (Income) and Expense

 

$

15

 

$

(3

)

$

12

 

Total Assets

 

$

25,708

 

$

16,936

 

$

42,644

 

Capital Expenditures

 

$

2,266

 

$

80

 

$

2,346

 

Depreciation

 

$

104

 

$

63

 

$

167

 

Amortization

 

$

224

 

$

26

 

$

250